靶向治疗联合扶正抗癌汤治疗非小细胞肺癌的效果分析  

Effect of Targeted Therapy Combined with Fuzheng Kangai Decoction on Non-small Cell Lung Cancer

作　　者：郭志平 马倩倩 曹鹏飞 Guo Zhiping;Ma Qianqian;Cao Pengfei(Department of Oncology and Hematology,Ili Kazakh Autonomous Prefecture Kuitun Hospital,Kuitun 833200,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]伊犁哈萨克自治州奎屯医院肿瘤血液科,新疆维吾尔自治区奎屯833200

出　　处：《中外医药研究》2024年第30期88-90,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

基　　金：2023年奎屯市科技计划项目(编号:202305)。

摘　　要：目的:分析靶向治疗联合扶正抗癌汤治疗非小细胞肺癌的效果。方法:选取2022年1—12月伊犁哈萨克自治州奎屯医院收治的60例非小细胞肺癌患者为研究对象,随机分为对照组与观察组,各30例。对照组口服靶向药治疗,观察组在靶向药治疗基础上联合扶正抗癌汤治疗。对比两组治疗效果、临床症状积分、免疫指标、不良反应、生存率。结果:观察组有效率高于对照组(P=0.038);治疗后,两组咳嗽、胸痛、血痰、气短评分降低,观察组低于对照组(P<0.05);治疗后,两组CD3^(+)、CD4^(+)水平升高,CD8^(+)水平降低,观察组优于对照组(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05);观察组1年生存率高于对照组(P=0.037)。结论:在对非小细胞肺癌患者进行靶向治疗时辅助使用扶正抗癌汤可提高治疗效果,减轻临床症状,改善免疫功能。Objective:To analyze the effect of targeted therapy combined with Fuzheng Kangai Decoction on non-small cell lung cancer.Methods:Sixty patients with non-small cell lung cancer treated in Ili Kazakh Autonomous Prefecture Kuitun Hospital from January to December 2022 were selected as the study objects,and randomly divided into control group and observation group,with thirty cases in each group.The control group was treated with oral targeted drugs,and the observation group was treated with Fuzheng Kangai Decoction on the basis of targeted drugs.The therapeutic effect,clinical symptom score,immune index,adverse reaction and survival rate were compared between the two groups.Results:The effective rate of observation group was higher than that of control group(P=0.038);after treatment,the scores of cough,chest pain,blood sputum and shortness of breath were decreased in both groups,and the observation group was lower than the control group(P<0.05);after treatment,CD3^(+)and CD4^(+)levels increased and CD8^(+)levels decreased in both groups,and the observation group was better than the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05);the 1-year survival rate of observation group was higher than that of control group(P=0.037).Conclusion:The adjuvant use of Fuzheng Kangai Decoction in the targeted therapy of patients with non-small cell lung cancer can improve the therapeutic effect,reduce clinical symptoms and improve immune function.

关 键 词：非小细胞肺癌 靶向治疗 扶正抗癌汤 

分 类 号：R734.2[医药卫生—肿瘤]